Published date: Dec 26 2018

Journal Title: Sudan Journal of Medical Sciences

Issue title: Sudan JMS: Volume 13 (2018), Issue No. 4

Pages: 230–239

DOI: 10.18502/sjms.v13i4.3593

Enaam Abdel-Rhman Abdel-Gaderenaamresearch@gmail.com

Nada Hassan Eltayeb

Tasniem Ahmed Eltahir

Osama Ali Altayeb

Eman Abbass Fadul

Eldirdiri M. Abdel Rahman

Tarig H. Merghani

Background: Chronic lymphocytic leukemia is the most common form of leukemia in adults. The prognostic impact of ZAP-70 in CLL has been reported in several studies. The aim of conducting this study was to investigate the prevalence of ZAP-70 in Sudanese patients with chronic lymphocytic leukemia attending Khartoum Oncology Hospital.
Materials and Methods: A total of 93 newly diagnosed patients with chronic lymphocytic leukemia were enrolled in this study. Lymphadenopathy and organomegaly were assessed in all participants using clinical examination, chest radiography, and abdominal ultrasound. Full blood count was carried out by an automated hematology analyzer. ZAP-70 was evaluated using flowcytometry on peripheral blood samples. ZAP-70 was defined as positive expression at a cutoff level of 20%.

Results: There were 63 (67.7%) males and 30 (32.3%) females and the median age of the group was 63 years; 68 patients (73.1%) were presented with anemia and 66
(70.9%) had lymphadenopath;y. Majority of our patients 35 (37.6%) were in Rai stage IV. ZAP-70 positivity was detected in 21 patients (22.6%). There was no statistically significant association of ZAP-70 with age, sex, lymphadenopathy, organomegaly, hemoglobin concentration, total white blood cell count, platelet count and Rai staging system (p-value > 0.05).

Conclusion: Only 21 patients (22.6%) were ZAP-70 positive. There was no association between ZAP-70 and the study variables. Further studies to evaluate prognostic role of ZAP-70 in Sudanese patients with chronic lymphocytic leukemia are recommended.

[1] Rozman, C. and Montserrat, E. (1995). Chronic lymphocytic leukaemia. The New England Journal of Medicine, vol. 333, pp. 1052–1057.

[2] Rodringuez-Vicente, A. E., Diaz, M. G., and Hernandez-Rivas, M. J. (2013). Chronic lymphocytic leukemia: A clinical and molecular heterogenous disease. Cancer Genetics, vol. 206, no. 3, pp. 49–62.

[3] Stevenson, F. K. and Caligaris-Cappio, F. (2004). Chronic lymphocytic leukaemia: Revelations from the B-cell receptor. Blood, vol. 103, pp. 4389–4395.

[4] Chiorazzi, N., Rai, K. R., and Ferrarini, M. Chronic lymphocytic leukaemia. (2005). The New England Journal of Medicine, vol. 352, pp. 804–815.

[5] Binet, J. L., Caligaris-Cappio, F., Catovsky, D., et al. (2006). Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood, vol. 107, pp. 859–861.

[6] Molica, S. (1991). Progression and survival studies in early chronic lymphocytic leukemia. Blood, vol. 78, pp. 895–899.

[7] Montserrat, E., Sanchez-Bisono, J., Vinolas, N., et al. (1986). Lymphocyte doubling time in chronic lymphocytic leukaemia: Analysis of its prognostic significance. British Journal of Haematology, vol. 62, pp. 567–575.

[8] Hamblin, T. J., Davis, Z., Gardiner, A., et al. (1999). Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood, vol. 94, pp. 1848–1854.

[9] Gogia, A., Sharma, A., Raina, V., et al. (2013). Prevalence of ZAP-70 and CD 38 in Indian chronic lymphocytic leukemia patients. Indian Journal of Cancer, vol. 50, no. 4, pp. 333–336.

[10] Crespo, M., Bosch, F., Villamor, N., et al. (2003). ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. The New England Journal of Medicine, vol. 348, pp. 1764–1775.

[11] Rassenti, L. Z., Huynh, L., Toy, T. L., et al. (2004). ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. The New England Journal of Medicine, vol. 351, pp. 893–901.

[12] Orchard, J. A., Ibbotson, R. E., Davis, Z., et al. (2004). ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet, vol. 363, pp. 105–111.

[13] Herishanu, Y., Kay, S., Rogowski, O., et al. (2005). T-cell ZAP-70 overexpression in chronic lymphocytic leukemia (CLL) correlates with CLL cell ZAP-70 levels, clinical stage and disease progression. Leukemia, vol. 19, pp. 1289–1291.

[14] Nabhan, C., Raca, G., and Wang, Y. L. (October 2015). Predicting prognosis in chronic lymphocytic leukemia in the contemporary era. JAMA Oncology, vol. 1, no. 7, pp. 965– 974.

[15] Ghielmini, M., Vitolo, U., Kimby, E., et al. (2013). Panel members of the 1st ESMO consensus conference on malignant lymphoma. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Annals
of Oncology, vol. 24, no. 3, pp. 561–576.

[16] Cheson, B. D., Bennett, J. M., Grever, M., et al. (1996). National Cancer Institutesponsored working group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood, vol. 87, pp. 4990–4997.

[17] Hallek, M., Cheson, B. D., Catovsky, D., et al. (2008). Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer InstituteWorking Group 1996 guidelines. Blood, vol. 111, pp. 5446–5456.

[18] Rai, K. R., Sawitsky, A., Cronkite, E. P., et al. (1975). Clinical staging of chronic lymphocytic leukemia. Blood; vol. 46, no. 2, pp. 219–234.

[19] Del Principe, M. I., Del Poeta, G., Buccisano, F., et al. (2006). Clinical significance of ZAP 70 protein expression in B cell Chronic Lymphocytic Leukemia. Blood, vol. 108, pp. 853–861.

[20] Hus, I., Podhorecka, M., Bojarska-Junak, A., et al. (2006). The clinical significance of ZAP70 and CD 38 expression in B cell chronic lymphocytic leukemia. Annals of Oncology, vol. 17, pp. 683–690.

[21] D’Arena, G., Tarnani, M., Rumi, C., et al. (2007). Prognostic significance of combined analysis of ZAP 70 and CD 38 in chronic lymphocytic leukemia. Am J Haematol;82:787-91.

[22] Del Poeta, G., Maurillo, L., Venditti, A., et al. (2001). Clinical significance of CD 38 expression in chronic lymphocytic leukemia. Blood, vol. 98, pp. 2633–2639.

[23] El-Kinawy, N. S., Sharaf, H. M., and Abd El-Hamid, M. (2012). Prognostic significance of del 17p, ZAP-70 and CD38 as independent indicators for B-CLL: Correlation to response to treatment and disease outcome. The Egyptian Journal of Medical Human Genetics, vol. 13, pp. 173–181.

[24] Rossi, F. M., Del Principe, M. I., Rossi, D., et al. (2010). Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: Mean fluorescence intensity T/B ratio versus percentage of positive cells. Journal of Translational Medicine, vol. 8, no. 23.

[25] Catherwood, M. A., Matthews, C., Niblock, R., et al. (2006). ZAP-70 mRNA quantification in B-cell chronic lymphocytic leukaemia. European Journal of Haematology, vol. 76, no. 4, pp. 294–298.

[26] Schroers, R., Griesinger, F., Trumper, L., et al. (2005). Combined analysis of ZAP 70 and CD 38 expression as a predictor of disease progression in B cell chronic lymphocytic leukemia. Leukemia, vol. 19, pp. 750–758.